[Modern approaches to beta-interferon application in therapy of multiple sclerosis]

Recently a disease-modifying treatment of multiple sclerosis (MS) became possible. The first choice in this kind of treatment is the use of beta-interferons. The longest history has the studies of beta-interferon-1b, which has a beneficial effect on the course of MS reducing the annual exacerbation rate and slowing the disability progression. This kind of treatment is very expensive and has only a moderate influence on the disease course, only slowing its progression, but still are widely used and causes attention all over the world. The most important question is the appropriate selection of MS patients for this kind of treatment. Numerous regional neurological community has elaborated special recommendations for the use of this treatment. These recommendations are usually base on the data of clinical trials, own experience and current financial situation (to cover the high cost of this treatment). Analyses of the last data on the mechanisms of beta-interferons treatment showed several specific and nonspecific effects. In recently published studies beta-interferon-1b was shown to slow the progression of confirmed disability in secondary progressive MS and delay the switch from relapsing/remitting to secondary progressive MS. Still the most beneficial clinical effect is seen in relapsing/remitting cases. The problem of neutralizing antibodies (NAT) and treatment of possible side effects seem now not to be so principle. Recommendations for the selection of patients with MS for treatment with beta-interferon were proposed.